RJA
NDRA icon

Raymond James & Associates’s ENDRA Life Sciences NDRA Stock Holding History

Raymond James & Associates’s Portfolio NDRA Stock Details NDRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed -$49K – 4225
2021
Q4 		$49K Buy
+2
New +$84.9K ﹤0.01% 3949

Other funds holding NDRA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
5L
55I LLC Boston, Massachusetts $3.58B AUM 17.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Raymond James & Associates's NDRA Position: Q1 2022 in Review

Raymond James & Associates sold out of ENDRA Life Sciences (NDRA) in Q1 2022, closing a stake of 2 shares — an estimated $49K sold.

Raymond James & Associates first reported a position in NDRA in Q4 2021 and held it in 1 quarter. The position peaked at $49K in Q4 2021. 13 funds tracked by Wall St. Rank hold NDRA as of Q1 2022.

  • Raymond James & Associates reported no remaining ENDRA Life Sciences position as of Q1 2022 after selling out during the quarter.
  • Raymond James & Associates sold 2 ENDRA Life Sciences shares in Q1 2022, an estimated $49K.
  • Raymond James & Associates first reported a position in ENDRA Life Sciences in Q4 2021 and held it in 1 quarter.
  • Raymond James & Associates's ENDRA Life Sciences position peaked at $49K in Q4 2021.
  • 13 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q1 2022.

Based on Raymond James & Associates's 13F filing for Q1 2022, filed 11 May 2022.